The purpose of the study was to introduce mycophenolate mofetil (MMF) in liver transplant recipients with renal dysfunction to decrease calcineurin inhibitor (CNI) dosages without increasing rejection risk. In this prospective, multicenter, randomized study, chronic CNI-related renal dysfunction was
Improvement of Renal Function After Conversion to Mycophenolate Mofetil Combined With Low-Level Calcineurin Inhibitor in Liver Transplant Recipients With Chronic Renal Dysfunction
✍ Scribed by C. Ponton; L. Vizcaíno; S. Tomé; E. Otero; E. Molina; J.F. Castroagudín; A. López-Lago; E. Varo Pérez
- Book ID
- 116936010
- Publisher
- Elsevier Science
- Year
- 2010
- Tongue
- English
- Weight
- 195 KB
- Volume
- 42
- Category
- Article
- ISSN
- 0041-1345
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Chronic renal dysfunction is a frequent and severe complication in solid-organ transplant recipients. Calcineurin inhibitors (CNIs) are the main pathogenic factors of renal dysfunction. Switching from CNIs to nonnephrotoxic drugs, such as mammalian target of rapamycin inhibitors (everolimus and siro
Calcineurin inhibitors (CNIs) are the cornerstone of immunosuppression after liver transplantation. However, CNI treatment is frequently associated with chronic renal failure (CRF). The reduction or interruption of CNI may reduce renal failure. We prospectively studied 49 liver recipients treated wi